吲哚布芬联合替格瑞洛对比阿司匹林联合替格瑞洛 用于经皮冠状动脉介入治疗术后的成本-效用分析.

OBJECTIVE: To evaluate the cost-effectiveness of indobufen combined with ticagrelor versus aspirin combined with ticagrelor for antiplatelet therapy after percutaneous coronary intervention (PCI). METHODS: Markov model was used to simulate the economic outcomes of patients treated with indobufen + ticagrelor and aspirin + ticagrelor for antiplatelet therapy after PCI. Quality-adjusted life years (QALY) was set as the effectiveness measure, the total costs, total effectiveness and incremental cost-effectiveness ratios ( ICER) of two treatment regimens were calculated. RESULTS: Over a 10-year time horizon, the total cost of indobufen + ticagrelor was 172 292. 28 yuan, while the total cost of aspirin + ticagrelor was 169 950. 51 yuan. The QALY gained with indobufen + ticagrelor and aspirin + ticagrelor were 6. 540 and 6. 335, respectively. The ICER of indobufen + ticagrelor to aspirin + ticagrelor was 11 472. 09 yuan / QALY, lower than per capita GDP in China. These results suggested that indobufen+ticagrelor is significantly better than aspirin+ticagrelor in cost-effectiveness. Sensitivity analysis demonstrated that the results of the study were robust and reliable. CONCLUSIONS: Results of the study indicate that indobufen + ticagrelor is more cost-effectiveness than aspirin + ticagrelor under the current economic conditions in China, and can be used as the first selection of antiplatelet therapy for patients after PCI. [ABSTRACT FROM AUTHOR]